trial

The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia

NCTId NCT01874756
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 95 (actual)
Sponsored by Indiana University
Primary completion 2017-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
95 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2013-06
Primary completion
2017-12
Eligibility
MALE · 18 Years · 65 Years

Interventions & indications

Drugs
LY500307 150mgLY500307 75mgLY500307 25mg

Sponsors

Indiana UniversityLead Sponsor
Eli Lilly and CompanyCollaborator

Investigators

1
Alan Breier, MDPrincipal Investigator

Sites

4 total
Indianapolis, United StatesIndianapolis, United StatesIndianapolis, United StatesIndianapolis, United States

Linked catalysts

1
The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) — primary completion2017-12

Facts & assertions

4 sourced
Enrollment
95
Phase
PHASE2
Primary Completion Date
2017-12
Status
TERMINATED
relationships
The graph out of here
drug
LY500307 150mg
drug
LY500307 75mg
drug
LY500307 25mg
drug
lead_sponsor
Indiana University
company
collaborator
Eli Lilly and Company
company
indication
Schizophrenia
indication
Schizophrenia
indication
Cognitive Dysfunction
indication
investigator
Alan Breier, MD
person